Document 0842
 DOCN  M9590842
 TI    Cyclosporin A/VP-16 produced immunity to L1210 leukemia: the
       participation of cytotoxic CD8 T-lymphocytes.
 DT    9509
 AU    Slater LM; Sweet P; Stupecky M; Reynolds JT; Department of Medicine,
       University of California at Irvine 92717,; USA.
 SO    Clin Immunol Immunopathol. 1995 Jun;75(3):239-45. Unique Identifier :
       AIDSLINE MED/95285612
 AB    The role of the immune response in the chemotherapeutic cure of an
       intact host with neoplasia is not well defined. We have previously shown
       that the addition of cyclosporin A to VP-16 therapy of BDF/1 mice with
       L1210 leukemia produces immunity to leukemia in long-surviving host
       animals. We now characterize this immunity as being tumor specific and
       related to the participation of CD8 T-lymphocytes. Splenocytes derived
       from L1210 leukemia immune mice are cytotoxic to L1210 cells after in
       vitro restimulation, compared to splenocytes harvested from nonimmune
       control mice. This cytotoxicity is lost by CD8 T-lymphocyte depletion
       and persists in Ia antigen blocking experiments. Cytotoxicity is
       selective for L1210 leukemia compared to P388 leukemia, an alternate Ia
       antigen expressing methylcholanthrine-induced acute lymphoid leukemia,
       and L1210 leukemia-immune mice remain susceptible to P388 leukemia in
       vivo demonstrating specificity of the immune response generated by
       cyclosporin A/VP-16 therapy.
 DE    Animal  Cyclosporine/*ADMINISTRATION & DOSAGE  Cytotoxicity, Immunologic
       CD8-Positive T-Lymphocytes/*IMMUNOLOGY  Etoposide/*ADMINISTRATION &
       DOSAGE  Immunity, Cellular  Immunization, Passive  Leukemia L1210/DRUG
       THERAPY/*IMMUNOLOGY  Lymphocyte Depletion  Mice  Spleen/IMMUNOLOGY
       Support, Non-U.S. Gov't  T-Lymphocytes, Cytotoxic/*IMMUNOLOGY  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).